97 related articles for article (PubMed ID: 17766700)
1. Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-beta inhibitor, in healthy subjects.
Welch PA; Sinha VP; Cleverly AL; Darstein C; Flanagan SD; Musib LC
J Clin Pharmacol; 2007 Sep; 47(9):1138-51. PubMed ID: 17766700
[TBL] [Abstract][Full Text] [Related]
2. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Carducci MA; Musib L; Kies MS; Pili R; Truong M; Brahmer JR; Cole P; Sullivan R; Riddle J; Schmidt J; Enas N; Sinha V; Thornton DE; Herbst RS
J Clin Oncol; 2006 Sep; 24(25):4092-9. PubMed ID: 16943527
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose escalation and pharmacokinetic study of oral enzastaurin (LY317615) in advanced solid tumors.
Mukohara T; Nagai S; Koshiji M; Yoshizawa K; Minami H
Cancer Sci; 2010 Oct; 101(10):2193-9. PubMed ID: 20707806
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
5. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
[TBL] [Abstract][Full Text] [Related]
6. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
Rosen LS; Kurzrock R; Mulay M; Van Vugt A; Purdom M; Ng C; Silverman J; Koutsoukos A; Sun YN; Bass MB; Xu RY; Polverino A; Wiezorek JS; Chang DD; Benjamin R; Herbst RS
J Clin Oncol; 2007 Jun; 25(17):2369-76. PubMed ID: 17557949
[TBL] [Abstract][Full Text] [Related]
7. Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL.
Barilla D; Prasad P; Hubert M; Gumbhir-Shah K
Biopharm Drug Dispos; 2004 Mar; 25(2):51-9. PubMed ID: 14872552
[TBL] [Abstract][Full Text] [Related]
8. Single- and multiple-dose pharmacokinetics, safety, and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers.
Othman AA; Lenz RA; Zhang J; Li J; Awni WM; Dutta S
J Clin Pharmacol; 2011 Apr; 51(4):512-26. PubMed ID: 20495134
[TBL] [Abstract][Full Text] [Related]
9. Randomized, crossover, single-blind, placebo-controlled, human pharmacology clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: multiple-dose pharmacokinetics.
Algorta J; Pena MA; Alvarez A; Maraschiello C; Maruhn D; Windisch M; Mucke HA
Int J Clin Pharmacol Ther; 2009 Jul; 47(7):483-90. PubMed ID: 19640356
[TBL] [Abstract][Full Text] [Related]
10. Single-dose, placebo-controlled, phase I study of oral dolasetron.
Dixon RM; Cramer M; Shah AK; Whitmore J; Benedict CR; Hahne WF
Pharmacotherapy; 1996; 16(2):245-52. PubMed ID: 8820468
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
12. Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor.
Ford SL; Reddy YS; Anderson MT; Murray SC; Fernandez P; Stein DS; Johnson MA
Antimicrob Agents Chemother; 2006 Jun; 50(6):2201-6. PubMed ID: 16723584
[TBL] [Abstract][Full Text] [Related]
13. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.
Faessel HM; Gibbs MA; Clark DJ; Rohrbacher K; Stolar M; Burstein AH
J Clin Pharmacol; 2006 Dec; 46(12):1439-48. PubMed ID: 17101743
[TBL] [Abstract][Full Text] [Related]
14. Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers.
RodrÃguez CA; Azie NE; Adams G; Donaldson K; Francom SF; Staton BA; Bombardt PA
J Clin Pharmacol; 2004 Mar; 44(3):276-83. PubMed ID: 14973308
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Christopher R; Covington P; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
Clin Ther; 2008 Mar; 30(3):513-27. PubMed ID: 18405789
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
17. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
Dunbar JL; Turncliff RZ; Dong Q; Silverman BL; Ehrich EW; Lasseter KC
Alcohol Clin Exp Res; 2006 Mar; 30(3):480-90. PubMed ID: 16499489
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, and single- and multiple-dose pharmacokinetics of piperaquine phosphate in healthy subjects.
Ahmed T; Sharma P; Gautam A; Varshney B; Kothari M; Ganguly S; Moehrle JJ; Paliwal J; Saha N; Batra V
J Clin Pharmacol; 2008 Feb; 48(2):166-75. PubMed ID: 18199893
[TBL] [Abstract][Full Text] [Related]
19. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Mita MM; Rowinsky EK; Forero L; Eckhart SG; Izbicka E; Weiss GR; Beeram M; Mita AC; de Bono JS; Tolcher AW; Hammond LA; Simmons P; Berg K; Takimoto C; Patnaik A
Cancer Chemother Pharmacol; 2007 Feb; 59(2):165-74. PubMed ID: 16736151
[TBL] [Abstract][Full Text] [Related]
20. Multiple-dose, placebo-controlled, phase I study of oral dolasetron.
Hunt TL; Cramer M; Christy-Bittel J; Shah AK; Meyerson LJ; Benedict CR; Hahne WF
Pharmacotherapy; 1996; 16(2):253-60. PubMed ID: 8820469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
